Gradipore board recruits former Sirtex CEO
Tuesday, 26 August, 2003
Former Sirtex Medical CEO Dr Colin Sutton has joined the board of Gradipore as a non-executive director.
According to Gradipore chairman Prof Jeremy Davis, Sutton's breadth of skills and experience will be fundamental to the current focus on the commercialisation of Gradipore's technology.
"His role as CEO of Sirtex Medical, where he took a start-up company through an IPO to a market capitalisation in excess of $273 million in three years was remarkable. This experience, combined with his earlier experience of building a range of businesses involved in the biomedical field make him an ideal addition to the Gradipore board," said Davis in a statement.
In addition to his position on the Gradipore board, Sutton is a non-executive director of cancer diagnostics company Polartechnics.
Sutton retired from his position as CEO of Sirtex at the end of June following the failure of a takeover bid by US company Cephalon.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
